Methods for external control groups for single arm trials or long‐term uncontrolled extensions to randomized clinical trials

Purpose Clinical trials compare outcomes among patients receiving study treatment with comparators drawn from the same source. These internal controls are missing in single arm trials and from long‐term extensions (LTE) of trials including only the treatment arm. An external control group derived fr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacoepidemiology and drug safety 2020-11, Vol.29 (11), p.1382-1392
Hauptverfasser: Seeger, John D., Davis, Kourtney J., Iannacone, Michelle R., Zhou, Wei, Dreyer, Nancy, Winterstein, Almut G., Santanello, Nancy, Gertz, Barry, Berlin, Jesse A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1392
container_issue 11
container_start_page 1382
container_title Pharmacoepidemiology and drug safety
container_volume 29
creator Seeger, John D.
Davis, Kourtney J.
Iannacone, Michelle R.
Zhou, Wei
Dreyer, Nancy
Winterstein, Almut G.
Santanello, Nancy
Gertz, Barry
Berlin, Jesse A.
description Purpose Clinical trials compare outcomes among patients receiving study treatment with comparators drawn from the same source. These internal controls are missing in single arm trials and from long‐term extensions (LTE) of trials including only the treatment arm. An external control group derived from a different setting is then required to assess safety or effectiveness. Methods We present examples of external control groups that demonstrate some of the issues that arise and make recommendations to address them through careful assessment of the data source fitness for use, design, and analysis steps. Results Inclusion and exclusion criteria and context that produce a trial population may result in trial patients with different clinical characteristics than are present in an external comparison group. If these differences affect the risk of outcomes, then a comparison of outcome occurrence will be confounded. Further, patients who continue into LTE may differ from those initially entering the trial due to treatment effects. Application of appropriate methods is needed to make valid inferences when such treatment or selection effects are present. Outcome measures in a trial may be ascertained and defined differently from what can be obtained in an external comparison group. Differences in sensitivity and specificity for identification or measurement of study outcomes leads to information bias that can also invalidate inferences. Conclusion This review concentrates on threats to the valid use of external control groups both in the scenarios of single arm trials and LTE of randomized controlled trials, along with methodological approaches to mitigate them.
doi_str_mv 10.1002/pds.5141
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7756307</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2461096908</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4191-71abae2d0afc5f8e006e6a63e432e8a23f5a7c56b6592aeef8a002a0bcac14833</originalsourceid><addsrcrecordid>eNp1kc1u1TAQhS0Eon9IPAGyxKabtHZiO8kGCRVoKxWBVFhbc53JrSvHvtgJpSyqPgLPyJPU6b2UH4nVWD5nvhnNIeQ5ZwecsfJw1aUDyQV_RLY5a9uCS1k_nt-yKhqp2i2yk9IlY1lrxVOyVZWtErlhm9y8x_EidIn2IVL8NmL04KgJfozB0WUM02qtJeuXDinEgY7Rgks0f7rglz9vf-SugU5-0-Wwuyf5ZINPdAw0gu_CYL9nwTjrrckj1pA98qTPBZ9t6i75_O7tp6OT4uzD8enR67PCCN7youawACw7Br2RfYOMKVSgKhRViQ2UVS-hNlItlGxLQOwbyGcBtjBguGiqape8WnNX02LAzmDeFJxeRTtAvNYBrP5b8fZCL8NXXddSVazOgP0NIIYvE6ZRDzYZdA48hinpUggpSsHUbH35j_UyTPNZZ5fK-aiWNb-BJoaUIvYPy3Cm51B1DlXPoWbriz-XfzD-SjEbirXhyjq8_i9If3xzfg-8Az65sG0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2461096908</pqid></control><display><type>article</type><title>Methods for external control groups for single arm trials or long‐term uncontrolled extensions to randomized clinical trials</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Seeger, John D. ; Davis, Kourtney J. ; Iannacone, Michelle R. ; Zhou, Wei ; Dreyer, Nancy ; Winterstein, Almut G. ; Santanello, Nancy ; Gertz, Barry ; Berlin, Jesse A.</creator><creatorcontrib>Seeger, John D. ; Davis, Kourtney J. ; Iannacone, Michelle R. ; Zhou, Wei ; Dreyer, Nancy ; Winterstein, Almut G. ; Santanello, Nancy ; Gertz, Barry ; Berlin, Jesse A.</creatorcontrib><description>Purpose Clinical trials compare outcomes among patients receiving study treatment with comparators drawn from the same source. These internal controls are missing in single arm trials and from long‐term extensions (LTE) of trials including only the treatment arm. An external control group derived from a different setting is then required to assess safety or effectiveness. Methods We present examples of external control groups that demonstrate some of the issues that arise and make recommendations to address them through careful assessment of the data source fitness for use, design, and analysis steps. Results Inclusion and exclusion criteria and context that produce a trial population may result in trial patients with different clinical characteristics than are present in an external comparison group. If these differences affect the risk of outcomes, then a comparison of outcome occurrence will be confounded. Further, patients who continue into LTE may differ from those initially entering the trial due to treatment effects. Application of appropriate methods is needed to make valid inferences when such treatment or selection effects are present. Outcome measures in a trial may be ascertained and defined differently from what can be obtained in an external comparison group. Differences in sensitivity and specificity for identification or measurement of study outcomes leads to information bias that can also invalidate inferences. Conclusion This review concentrates on threats to the valid use of external control groups both in the scenarios of single arm trials and LTE of randomized controlled trials, along with methodological approaches to mitigate them.</description><identifier>ISSN: 1053-8569</identifier><identifier>EISSN: 1099-1557</identifier><identifier>DOI: 10.1002/pds.5141</identifier><identifier>PMID: 32964514</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Inc</publisher><subject>Clinical trials ; external control ; long‐term extension (LTE) ; Patients ; pharmacoepidemiology ; real world data (RWD) ; single‐arm RCT</subject><ispartof>Pharmacoepidemiology and drug safety, 2020-11, Vol.29 (11), p.1382-1392</ispartof><rights>2020 The Authors. published by John Wiley &amp; Sons Ltd.</rights><rights>2020 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley &amp; Sons Ltd.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4191-71abae2d0afc5f8e006e6a63e432e8a23f5a7c56b6592aeef8a002a0bcac14833</citedby><cites>FETCH-LOGICAL-c4191-71abae2d0afc5f8e006e6a63e432e8a23f5a7c56b6592aeef8a002a0bcac14833</cites><orcidid>0000-0002-8020-3144</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpds.5141$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpds.5141$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32964514$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seeger, John D.</creatorcontrib><creatorcontrib>Davis, Kourtney J.</creatorcontrib><creatorcontrib>Iannacone, Michelle R.</creatorcontrib><creatorcontrib>Zhou, Wei</creatorcontrib><creatorcontrib>Dreyer, Nancy</creatorcontrib><creatorcontrib>Winterstein, Almut G.</creatorcontrib><creatorcontrib>Santanello, Nancy</creatorcontrib><creatorcontrib>Gertz, Barry</creatorcontrib><creatorcontrib>Berlin, Jesse A.</creatorcontrib><title>Methods for external control groups for single arm trials or long‐term uncontrolled extensions to randomized clinical trials</title><title>Pharmacoepidemiology and drug safety</title><addtitle>Pharmacoepidemiol Drug Saf</addtitle><description>Purpose Clinical trials compare outcomes among patients receiving study treatment with comparators drawn from the same source. These internal controls are missing in single arm trials and from long‐term extensions (LTE) of trials including only the treatment arm. An external control group derived from a different setting is then required to assess safety or effectiveness. Methods We present examples of external control groups that demonstrate some of the issues that arise and make recommendations to address them through careful assessment of the data source fitness for use, design, and analysis steps. Results Inclusion and exclusion criteria and context that produce a trial population may result in trial patients with different clinical characteristics than are present in an external comparison group. If these differences affect the risk of outcomes, then a comparison of outcome occurrence will be confounded. Further, patients who continue into LTE may differ from those initially entering the trial due to treatment effects. Application of appropriate methods is needed to make valid inferences when such treatment or selection effects are present. Outcome measures in a trial may be ascertained and defined differently from what can be obtained in an external comparison group. Differences in sensitivity and specificity for identification or measurement of study outcomes leads to information bias that can also invalidate inferences. Conclusion This review concentrates on threats to the valid use of external control groups both in the scenarios of single arm trials and LTE of randomized controlled trials, along with methodological approaches to mitigate them.</description><subject>Clinical trials</subject><subject>external control</subject><subject>long‐term extension (LTE)</subject><subject>Patients</subject><subject>pharmacoepidemiology</subject><subject>real world data (RWD)</subject><subject>single‐arm RCT</subject><issn>1053-8569</issn><issn>1099-1557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kc1u1TAQhS0Eon9IPAGyxKabtHZiO8kGCRVoKxWBVFhbc53JrSvHvtgJpSyqPgLPyJPU6b2UH4nVWD5nvhnNIeQ5ZwecsfJw1aUDyQV_RLY5a9uCS1k_nt-yKhqp2i2yk9IlY1lrxVOyVZWtErlhm9y8x_EidIn2IVL8NmL04KgJfozB0WUM02qtJeuXDinEgY7Rgks0f7rglz9vf-SugU5-0-Wwuyf5ZINPdAw0gu_CYL9nwTjrrckj1pA98qTPBZ9t6i75_O7tp6OT4uzD8enR67PCCN7youawACw7Br2RfYOMKVSgKhRViQ2UVS-hNlItlGxLQOwbyGcBtjBguGiqape8WnNX02LAzmDeFJxeRTtAvNYBrP5b8fZCL8NXXddSVazOgP0NIIYvE6ZRDzYZdA48hinpUggpSsHUbH35j_UyTPNZZ5fK-aiWNb-BJoaUIvYPy3Cm51B1DlXPoWbriz-XfzD-SjEbirXhyjq8_i9If3xzfg-8Az65sG0</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Seeger, John D.</creator><creator>Davis, Kourtney J.</creator><creator>Iannacone, Michelle R.</creator><creator>Zhou, Wei</creator><creator>Dreyer, Nancy</creator><creator>Winterstein, Almut G.</creator><creator>Santanello, Nancy</creator><creator>Gertz, Barry</creator><creator>Berlin, Jesse A.</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8020-3144</orcidid></search><sort><creationdate>202011</creationdate><title>Methods for external control groups for single arm trials or long‐term uncontrolled extensions to randomized clinical trials</title><author>Seeger, John D. ; Davis, Kourtney J. ; Iannacone, Michelle R. ; Zhou, Wei ; Dreyer, Nancy ; Winterstein, Almut G. ; Santanello, Nancy ; Gertz, Barry ; Berlin, Jesse A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4191-71abae2d0afc5f8e006e6a63e432e8a23f5a7c56b6592aeef8a002a0bcac14833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Clinical trials</topic><topic>external control</topic><topic>long‐term extension (LTE)</topic><topic>Patients</topic><topic>pharmacoepidemiology</topic><topic>real world data (RWD)</topic><topic>single‐arm RCT</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seeger, John D.</creatorcontrib><creatorcontrib>Davis, Kourtney J.</creatorcontrib><creatorcontrib>Iannacone, Michelle R.</creatorcontrib><creatorcontrib>Zhou, Wei</creatorcontrib><creatorcontrib>Dreyer, Nancy</creatorcontrib><creatorcontrib>Winterstein, Almut G.</creatorcontrib><creatorcontrib>Santanello, Nancy</creatorcontrib><creatorcontrib>Gertz, Barry</creatorcontrib><creatorcontrib>Berlin, Jesse A.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pharmacoepidemiology and drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seeger, John D.</au><au>Davis, Kourtney J.</au><au>Iannacone, Michelle R.</au><au>Zhou, Wei</au><au>Dreyer, Nancy</au><au>Winterstein, Almut G.</au><au>Santanello, Nancy</au><au>Gertz, Barry</au><au>Berlin, Jesse A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Methods for external control groups for single arm trials or long‐term uncontrolled extensions to randomized clinical trials</atitle><jtitle>Pharmacoepidemiology and drug safety</jtitle><addtitle>Pharmacoepidemiol Drug Saf</addtitle><date>2020-11</date><risdate>2020</risdate><volume>29</volume><issue>11</issue><spage>1382</spage><epage>1392</epage><pages>1382-1392</pages><issn>1053-8569</issn><eissn>1099-1557</eissn><abstract>Purpose Clinical trials compare outcomes among patients receiving study treatment with comparators drawn from the same source. These internal controls are missing in single arm trials and from long‐term extensions (LTE) of trials including only the treatment arm. An external control group derived from a different setting is then required to assess safety or effectiveness. Methods We present examples of external control groups that demonstrate some of the issues that arise and make recommendations to address them through careful assessment of the data source fitness for use, design, and analysis steps. Results Inclusion and exclusion criteria and context that produce a trial population may result in trial patients with different clinical characteristics than are present in an external comparison group. If these differences affect the risk of outcomes, then a comparison of outcome occurrence will be confounded. Further, patients who continue into LTE may differ from those initially entering the trial due to treatment effects. Application of appropriate methods is needed to make valid inferences when such treatment or selection effects are present. Outcome measures in a trial may be ascertained and defined differently from what can be obtained in an external comparison group. Differences in sensitivity and specificity for identification or measurement of study outcomes leads to information bias that can also invalidate inferences. Conclusion This review concentrates on threats to the valid use of external control groups both in the scenarios of single arm trials and LTE of randomized controlled trials, along with methodological approaches to mitigate them.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>32964514</pmid><doi>10.1002/pds.5141</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-8020-3144</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1053-8569
ispartof Pharmacoepidemiology and drug safety, 2020-11, Vol.29 (11), p.1382-1392
issn 1053-8569
1099-1557
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7756307
source Wiley Online Library Journals Frontfile Complete
subjects Clinical trials
external control
long‐term extension (LTE)
Patients
pharmacoepidemiology
real world data (RWD)
single‐arm RCT
title Methods for external control groups for single arm trials or long‐term uncontrolled extensions to randomized clinical trials
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T08%3A32%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Methods%20for%20external%20control%20groups%20for%20single%20arm%20trials%20or%20long%E2%80%90term%20uncontrolled%20extensions%20to%20randomized%20clinical%20trials&rft.jtitle=Pharmacoepidemiology%20and%20drug%20safety&rft.au=Seeger,%20John%20D.&rft.date=2020-11&rft.volume=29&rft.issue=11&rft.spage=1382&rft.epage=1392&rft.pages=1382-1392&rft.issn=1053-8569&rft.eissn=1099-1557&rft_id=info:doi/10.1002/pds.5141&rft_dat=%3Cproquest_pubme%3E2461096908%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2461096908&rft_id=info:pmid/32964514&rfr_iscdi=true